Global Dialysis - ZS Pharma presenting data on it's GI potassium sorbent in patients taking RAAS inhibitors at ASH

ZS Pharma presenting data on it's GI potassium sorbent in patients taking RAAS inhibitors at ASH

ZS Pharma: The ZS003 sub-group analysis, which was pre-specified, specifically looked at patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) drug therapies, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and aldosterone blockers. Results demonstrated that both the 5g and 10g doses of ZS-9, administered once daily, controlled potassium at normal levels in these hyperkalemic patients.

...